For instance, the non-bile acid FXR agonist Tropifexor (LJN452) is being investigated in a double-blind, phase II, clinical trial in NASH patients (ClinicalTrials.gov identifier: NCT02855164). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.